What Researchers Did
Researchers reported long-term follow-up data from a pilot trial testing HBOT before umbilical cord blood stem cell transplantation in patients with hematologic malignancies, comparing outcomes to a historic control group.
What They Found
HBO-treated patients had better 6-month survival, lower relapse rates, less graft-versus-host disease (GVHD), and improved B-cell immune reconstitution compared to controls. However, 1-year survival did not significantly differ between groups, possibly due to small sample size. A stronger drop in erythropoietin after HBOT correlated with better outcomes.
What This Means for Canadian Patients
Cord blood transplantation is performed at Canadian transplant centers for patients who lack matched donors. This pilot study suggests HBOT before transplant may improve early engraftment and immune recovery. The erythropoietin response to HBOT could serve as a predictive biomarker for treatment response.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a small pilot trial compared against a historic control group; differences in treatment era, patient selection, and supportive care make comparisons unreliable.